Bryan D. Smith
Affiliations: | 2006 | Department of Biochemistry | University of Wisconsin, Madison, Madison, WI |
Google:
"Bryan Smith"Mean distance: 8.25 | S | N | B | C | P |
Parents
Sign in to add mentor| Ronald T. Raines | grad student | 2006 | UW Madison | |
| (Ribonuclease activity: Basis and control.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Caldwell TM, Mi Ahn Y, Bulfer SL, et al. (2022) Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 128928 |
| Smith BD, Kaufman MD, Wise SC, et al. (2021) Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Molecular Cancer Therapeutics |
| Gupta A, Singh J, García-Valverde A, et al. (2021) Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and Systemic Mastocytosis. Molecular Cancer Therapeutics |
| Somwar R, Hofmann NE, Smith B, et al. (2020) NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology. 3: 776 |
| Smith BD, Kaufman MD, Lu WP, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 35: 738-751.e9 |
| Smith BD, Vogeti L, Gupta A, et al. (2019) Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers Molecular Cancer Therapeutics. 18 |
| Harney AS, Karagiannis GS, Pignatelli J, et al. (2018) The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Molecular Cancer Therapeutics. 16: 2486-2501 |
| Smith BD, Kaufman MD, Gupta A, et al. (2018) Abstract 3925: Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618 Cancer Research. 78: 3925-3925 |
| Harney AS, Karagiannis GS, Pignatelli J, et al. (2017) The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors. Molecular Cancer Therapeutics |
| Janku F, Abdul Razak AR, Gordon MS, et al. (2017) Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. Journal of Clinical Oncology. 35: 2515-2515 |